Pipeline

+ mAb

Engineered

AML = Acute Myeloid Leukemia
T-ALL = T-cell Acute Lymphoblastic Leukemia
LBL = Lymphoblastic Lymphoma
mAb = Monoclonal Antibody

Co-development of Wugen products in China, Hong Kong, Taiwan, Macao, and Singapore

AML = Acute Myeloid Leukemia
T-ALL = T-cell Acute Lymphoblastic Leukemia
LBL = Lymphoblastic Lymphoma
mAb = Monoclonal Antibody

Co-development of Wugen products in China, Hong Kong, Taiwan, Macao, and Singapore

WU-NK-101

Opportunity to treat a wide variety of hematologic malignancies and solid tumors
Better target killing through increases in cytokine production
Enhanced ADCC for more robust response to antibody triggering
Improved balance of KIR activating and inhibitory signals
A Phase 1/2 clinical trial of WU-NK-101 (1:1) showed the therapy was well-tolerated, persistent, and active against AML

Opportunity to treat T-ALL, an orphan disease that is most common in children and young adults
Deletion of the target in CAR-T prevents CAR-T Vs. CAR-T killing (friendly-fire)
Disruption of the T-cell receptor enables the use of allogeneic donor T cells with reduced risk of Graft Vs. Host Disease
Use of allogeneic donors prevents malignant cell contamination
Clinical trials testing the safety and efficacy of WU-CART-007 are actively enrolling patients

4260 Forest Park Ave
Suite 100
St. Louis, MO 63108
(636) 385-5306

9880 Campus Point Dr
Suite 430
San Diego, CA 92121